ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for re-induction. Additional management of ALL subsets (T-ALL), CNS relapse, and the role of consolidation with allogeneic transplantation are addressed. Future research should evaluate these approaches with special attention to the unique AYA population and should evaluate quality of life outcomes.